iOnctura
Prescription Drugs · Biotechnology
$102.6Mtotal raised · 3 rounds on record
$86.4Mlatest round · Series B · Jun 2024 · 2 yr ago
3backers · Inkef, M Ventures
$2.7Mgrants · 1 grant · CORDIS
Overview
Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the.
Funding and backers
Total raised
$102.6M
3 rounds on record
Latest round
$86.4M
Series B · Jun 2024 · 2 yr ago
Team
201-500
employees, estimated range
Grants
$2.7M
1 grant · CORDIS
Backers
3
Inkef, M Ventures
The money's age
Long since its last round
28 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 20, 2024
Raised a round Series B $86.4M · PRNewswire
Oct 1, 2022
Won a grant $2.7M · CORDIS
Jan 22, 2020
Raised a round Series A $16.2M
2016
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jun 2024 | $86.4M | — | PRNewswire |
| Grant | Oct 2022 | $2.7M | — | CORDIS |
| Series A | Jan 2020 | $16.2M | — | medindia.net |
Registers and programsofficial lists and records that name the company
| Legal entity | Onctura SA | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Inkef 
M Ventures 
Vi Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
ABOUT What We Do Estrigenix Therapeutics, Inc. was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and…
We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent…
Luxna Biotech is a preclinical-stage Japanese biotechnology company that develops antisense oligonucleotide (ASO) therapeutics using novel…
Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and…
About TILT TILT Biotherapeutics is the world's leading company developing oncolytic immunotherapies to enable T-cell therapies for solid…
Oisín Biotechnologies develops genetic medicines to address age-related diseases.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Data & publication The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity 22 January 2026
Read more
Report
Press coverage Drug Discovery World Autotaxin inhibition: unlocking new frontiers in cancers and beyond 8 January 2026
Read more
Report
iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH
First patient dosed in Phase I/II HEMA-MED clinical trial (NCT06887803) evaluating the tolerability and efficacy profile of roginolisib (PI3Kδ inhibitor) plus...
Read more
Report
iOnctura reaches new clinical milestones in uveal melanoma (2024-12-11)
GENEVA and AMSTERDAM, Dec. 11, 2024/ PRNewswire/-- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today provides a clinical update on its lead asset, roginolisib. Results from the completed Phase I DION
Read more
Report
iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
/PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces that it has closed an EUR80...
Read more
Report
iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program
/PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival...
Read more
Report
iOnctura awarded EUR17.5 million funding from the EIC Accelerator for clinical development of novel pancreatic cancer therapy
Read more
Report
iOnctura to Present at ASCO IOA-244 Showing Highly Promising Impact on Overall Survival for Patients With Metastatic and Refractory Uveal Melanoma
Read more
Report
iOnctura to present at ASCO encouraging Phase Ib refractory uveal melanoma data for first semi-allosteric PI3Kδ inhibitor, IOA-244
Read more
Report
iOnctura PresentsPositive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies
GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data confirming the mode of action of its a
Read more
Report
Show more news